You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ARIKAYCE

Showing 1 - 13 of 13
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Volunteers Trial (Liposomal Amikacin for Inhalation)

Completed
  • Healthy Volunteers
  • Liposomal Amikacin for Inhalation
  • (no location specified)
Aug 11, 2023

Cystic Fibrosis Trial in Worldwide (Arikayce™)

Completed
Has Results
  • Cystic Fibrosis
  • Leuven, Belgium
  • +10 more
Jul 20, 2020

Pseudomonas Aeruginosa Infection Trial in Worldwide (Liposomal amikacin for inhalation (Arikayce™) using the PARI

Completed
Has Results
  • Pseudomonas Aeruginosa Infection
  • Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
  • Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
  • Vienna, Austria
  • +61 more
May 28, 2020

Cystic Fibrosis Trial in Worldwide (ARIKACE™, Placebo)

Completed
Has Results
  • Cystic Fibrosis
  • Leuven, Belgium
  • +10 more
Jul 20, 2020

Mycobacterium Infections, Nontuberculous Trial (LAI (Liposomal Amikacin for Inhalation) 590 mg)

Completed
Has Results
  • Mycobacterium Infections, Nontuberculous
  • LAI (Liposomal Amikacin for Inhalation) 590 mg
  • (no location specified)
Apr 22, 2020

Bronchiectasis Trial in Worldwide (280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™)

Completed
Has Results
  • Bronchiectasis
  • 280 mg Arikayce™
  • +3 more
  • Washington, District of Columbia
  • +17 more
Jun 20, 2019

Cystic Fibrosis Trial in United States (Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg)

Completed
Has Results
  • Cystic Fibrosis
  • Arikayce™ 560 mg
  • +4 more
  • Birmingham, Alabama
  • +18 more
May 14, 2019

NTM Lung Infection Due to MAC Trial (LAI 590 mg, Multi-drug regimen)

Completed
Has Results
  • NTM Lung Infection Due to MAC
  • LAI 590 mg
  • Multi-drug regimen
  • (no location specified)
Jan 21, 2020

Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical Trial in Portland, Tyler (LAI plus multi-drug regimen)

Completed
  • Mycobacterium Infections, Nontuberculous
  • Mycobacteria, Atypical
  • LAI plus multi-drug regimen
  • Portland, Oregon
  • +1 more
Mar 2, 2020

Mycobacterium Infections, Nontuberculous Trial in Worldwide (ALIS, Azithromycin, Ethambutol)

Active, not recruiting
  • Mycobacterium Infections, Nontuberculous
  • Birmingham, Alabama
  • +110 more
Jan 23, 2023

Mycobacterium Infections, Nontuberculous Trial in Worldwide (ALIS, Azithromycin, Ethambutol)

Recruiting
  • Mycobacterium Infections, Nontuberculous
  • Birmingham, Alabama
  • +172 more
Jan 23, 2023

Mycobacterium Infections, Nontuberculous Trial in Canada, United States (Liposomal amikacin for inhalation (LAI), )

Completed
Has Results
  • Mycobacterium Infections, Nontuberculous
  • Liposomal amikacin for inhalation (LAI)
  • placebo
  • Birmingham, Alabama
  • +18 more
Aug 6, 2019

Cystic Fibrosis Trial in Worldwide (Liposomal amikacin for inhalation)

Completed
Has Results
  • Cystic Fibrosis
  • Liposomal amikacin for inhalation
  • Vienna, Austria
  • +49 more
Jun 10, 2020